Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Rexall_Drugstore
|
| gptkbp:brand |
gptkb:Rexall
|
| gptkbp:clinical_trial |
ongoing
completed urticaria perennial allergic rhinitis seasonal allergic rhinitis |
| gptkbp:contains |
antihistamines
|
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to ingredients |
| gptkbp:dosage_form |
as directed by a physician
|
| gptkbp:first_introduced |
2000s
|
| gptkbp:formulation |
oral
topical intranasal |
| https://www.w3.org/2000/01/rdf-schema#label |
Rexall Allergy Products
|
| gptkbp:ingredients |
gptkb:Diphenhydramine
gptkb:Loratadine Cetirizine |
| gptkbp:interacts_with |
gptkb:beer
sedatives other antihistamines |
| gptkbp:invention |
patented
generic available |
| gptkbp:is_available_in |
gptkb:fragrance
gptkb:item tablets sugar-free options |
| gptkbp:is_used_for |
relief of allergy symptoms
|
| gptkbp:manufacturer |
Rexall Pharmacy Group Ltd.
|
| gptkbp:market |
over-the-counter
prescription available |
| gptkbp:marketed_as |
non-drowsy formula
|
| gptkbp:packaging |
bottles
blister packs |
| gptkbp:regulatory_compliance |
FDA approved
Health Canada approved |
| gptkbp:shelf_life |
2 years
|
| gptkbp:side_effect |
dizziness
nausea vomiting drowsiness constipation dry mouth |
| gptkbp:storage |
store in a cool, dry place
|
| gptkbp:target_audience |
gptkb:Person
adults |